drugset
drugset / Trial / NCT05176314

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants

NCT05176314 ↗

Phase 1 Completed 32 enrolled Loxo Oncology, Inc. Eli Lilly and Company · collab
NaSequentialOpen-labelBasic science

Summary

The main purpose of this study is to determine the effect of pirtobrutinib on the levels of rosuvastatin in the blood stream in healthy participants. This study will also evaluate the safety and tolerability of rosuvastatin when administered in combination with pirtobrutinib in healthy participants. This study will last up to approximately 26 days excluding screening period.

Timeline

Start
2022-01-11
Primary completion
2022-04-20
Completion
2022-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirtobrutinib Other / unclassified 200 mg Oral
Subject Rosuvastatin Small molecule 20 mg Oral

Indications

No indication recorded.